title: A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
authors.affiliation: Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.
authors.forename: O
authors.initials: O
authors.lastname: Rascol
authors.forename: A J
authors.initials: AJ
authors.lastname: Lees
authors.forename: J M
authors.initials: JM
authors.lastname: Senard
authors.forename: Z
authors.initials: Z
authors.lastname: Pirtosek
authors.forename: C
authors.initials: C
authors.lastname: Brefel
authors.forename: J L
authors.initials: JL
authors.lastname: Montastruc
authors.forename: D
authors.initials: D
authors.lastname: Fuell
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use; D009069:Movement Disorders / Q000188:drug therapy* / Q000503:physiopathology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D017448:Receptors, Dopamine D2 / Q000819:agonists*
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007211:Indoles; D017448:Receptors, Dopamine D2; C046649:ropinirole; D007980:Levodopa